ITM Isotope Technologies Munich has secured an exclusive global license for the clinical and commercial development of Debiopharm’s cancer imaging and treatment pair ITM-91/ITM-94D.
Formerly known as Debio 0228/0328, ITM-91/ITM-94D targets a surface protein expressed on solid tumors. ITM-91 is a lutetium-177-labeled radioligand therapeutic compound and ITM-94D is a gallium-68-labeled imaging agent. The pair is being investigated in the phase I/II clinical trial in patients with clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.
Under the agreement, Debiopharm will receive payments of approximately $331 million, as well as commercial milestones and royalties on potential future sales, ITM said.
![Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_depression.66cf997f7e441.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
